PharmiWeb.com - Global Pharma News & Resources
25-Mar-2021

Sustained Release Excipients Market Robust pace of Industry during 2018-2028

A recently released global market intelligence outlook on sustained release excipients forecasts the revenue through sustained release excipients to surpass a million dollar value by this year’s end, of which just-under 1/3rd share belongs to North America.The demand within the global sustained release excipients market has been rising on account of key improvements in the pharmaceutical industry. Sustained dosing of drugs holds immense significance for a range of industries, and hence, the use of sustained release excipients has become more pronounced in recent times

As a growing number of existing international patents are expiring and the prevalence of orthopedic disorders is increasing on the flipside, drug formulations and thereby sustained release excipients are constantly witnessing an impressive manufacturing outlook.

Research identifies the largest revenue shareholding categories in sustained release excipients marketplace on the basis of product type, end user, and route of administration.

  • Polymer is currently the largest product type category worth US$ 300 Mn, whereas gelatin represents the most opportunistic one.
  • While oral route of administration remains highly sought after, injectable is presumed to gradually take over.
  • Biopharmaceutical companies and CMOs pose fierce competition to pharmaceutical companies – the dominant end user of sustained release excipients.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7580

“The top five players leading the competition in global sustained release excipients landscape account for a collective revenue share of over 50%, whereas a number of relatively small companies represent the rest. A majority of competitors have a limited offering portfolio and significantly depend on product differentiation for an edge in niche treatment areas,” explains a senior research analyst. “Product innovation and market expansion have been the top developmental strategies of companies so far, which are now complemented with strategic partnerships,” the analyst adds further.

Multi-level Partnerships  The Key to Delivering Top Notch Excipient Formulations 

FMI underlines the critical role of strategic collaborations – between formulators of sustained release excipients and stakeholders across the value chain – in shaping growth of brands as well as the entire sustained release excipients ecosystem.

While partnerships are expected to prominently focus on spotting the key challenges facing manufacturers, continued education about functionality, variability, and consistency of sustained release excipients is also be an important objective. Drug product manufacturers working in tandem with formulators of sustained release excipients is helping companies deliver best-in-class solutions addressing the most prominent pull factors associated with sustained release excipients.

Preview Analysis On Sustained Release Excipients Market Segmentation By Product Type – Gelatin based Sustained Release Excipients Polymer based Sustained Release Excipients, minerals based Sustained Release Excipients, Sugars based Sustained Release Excipients, alcohol based Sustained Release Excipients, chitosan based Sustained Release Excipients; Route of Administration – oral, Injectable, Vaginal, and Ophthalmic: https://www.futuremarketinsights.com/checkout/7580

To best grasp real-time market needs, sustained release excipient formulators are most likely to strengthen interaction with end-use customers. This move offers a dual advantage as a developmental strategy – by helping manufacturers precisely understand and address the challenges facing pharmaceutical markets and stimulating development of new excipient formulations that tap into evolving needs.

A recent deal (2017) involving the combination of The Dow Chemical Company-DuPont-FMC (Health & Nutrition) has been a classic example of collaborative operation, involving channel partners as well as customers.

Request Report TOC @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-7580

More from Healthcare, Pharmaceuticals and Medical devices: 

  • Prefilled Formalin Vials Market Segmentation By Product Type – <10 mL, 10 – 20 mL, 20 – 40 mL, 40 – 60 mL, 60 – 90 mL, 90 – 500 mL, and 500 mL – 1 Litre
  • Opioid Withdrawal Management Market Segmented By Drugs – Opioid Agonists, Opioid Antagonists, Antidepressants; By Material of construction; By Application Area, By Distribution Channels
  • Acoustic Puncture Assist Devices Market Segmented By Drug Type; By Route of Administration, By Distribution Channel; End User: Hospitals, Ambulatory Surgical Centres, Specialty Clinics

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Editor Details

Last Updated: 25-Mar-2021